Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D
China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private...
CDE Issues New Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Drugs
The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...
Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
YHLO Biotech Partners with NCRCID to Develop Advanced Tuberculosis Diagnostics
China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National...
Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...
Lee’s Pharmaceutical Subsidiary Secures Distribution Deal for NVK002 in South Korea
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Shenzhen YHLO Biotech Partners with NCRCID for Advanced Tuberculosis Diagnostics
China-based Shenzhen YHLO Biotech Co., Ltd has announced a strategic partnership with the National Clinical...
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...
Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors
China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency...
CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Clinical R&D
The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million)...
CDE Releases Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Chemical Drugs
The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...
Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial...
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...